- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04301492
Tolerability, Safety and Efficacy of Vortioxetine (VorDe-PD)
Tolerability, Safety and Efficacy of Vortioxetine for Treatment od Depression in Parkinson's Disease: a 16 Week Open Label Study
Depression is a psychiatric disorder frequently found in Parkinson's disease (MP), affecting approximately 40-50% of patients and assuming the characteristics of major depression in 17% of cases. Vortioxetine is a new antidepressant, which inaugurates the class of "multimodal" antidepressants, able to exert modulation of serotonergic receptors, inhibit serotonin reuptake, modulate other neurotransmitters such as norepinephrine, dopamine, acetylcholine and histamine.
The primary endpoint of this study will be to verify safety and tolerability of vortioxetine in the treatment of sustained depression in PD. Safety will be assessed through the recording of treatment emergent adverse events (TEAE) and vital signs in each study visits and laboratory tests, ECG, physical and neurological examination at baseline and End of study. The non worsening of motor disability evaluated through Unified Parkinson's Disease Rating Scale (UPDRS) will be the tolerability end point.
The secondary endpoint will be to demonstrate the efficacy on depression: efficacy measures will include Hamilton Depression Rating Scale (HAM-D-17), Beck Depression Inventory (BDI), CGI-S and CGI-I.
Study Overview
Detailed Description
Depression is a psychiatric disorder frequently found in Parkinson's disease (MP), affecting approximately 40-50% of patients and assuming the characteristics of major depression in 17% of cases. Depression can also precede the onset of motor symptoms, playing an important role in the clinical course of the disease. Indeed, the presence of depression has been associated with greater disability, a more rapid cognitive decline, a higher mortality and a heavier burden for families and caregivers.The mechanisms underlying depression in MP are still not completely clarified, but autopsy and functional anatomy studies have demonstrated the presence of alterations in the limbic system and in noradrenergic and serotonergic nuclei of the brainstem.This dual nature accounts for the partial ineffectiveness of the common antidepressants that do not target alterations of the dopaminergic system.
Vortioxetine is a new antidepressant, which inaugurates the class of "multimodal" antidepressants, able to exert modulation of serotonergic receptors, inhibit serotonin reuptake, modulate other neurotransmitters such as norepinephrine, dopamine, acetylcholine and histamine.
Currently, tricyclic antidepressants and selective serotonin reuptake inhibitors represent the most common pharmacotherapy for depression treatment in PD patients. Although, they can induce or increase motor disability and other PD symptoms. It is of paramount importance finding a novel therapeutic approach able to positively impact on depression without worsening motor dysfunction. Therefore Vortioxetine can represent an innovative drug in the treatment of depression in PD thanks to its ability to increase dopaminergic neurotransmission in brain structures usually associated with depression.
This is a pilot, single centre, open label, ITT study which will be conducted at the l'IRCCS San Raffaele Pisana, under the responsibility of Fabrizio Stocchi, Principal Investigator.
The study will be conducted in accordance with the guidelines for Good Clinical Practice, in line with the law on the processing of patients' personal data and the principles of the Helsinki Declaration.
Patients will receive informed consent before they are included in the study.
Study population will include patients with idiopathic Parkinson's disease in stage I-III of the disease, suffering from sustained depression. 20 consecutive PD outpatient referred to the center for the study of Parkinson's disease and movement disorders of the IRCCS San Raffaele Pisana will be enrolled.
Since this is a pilot, monocentric study, calculation of the sample size is not required.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: fabrizio stocchi, MD PhD
- Phone Number: +39 0652252311
- Email: fabrizio.stocchi@sanraffaele.it
Study Locations
-
-
-
Roma, Italy, 00163
- Recruiting
- IRCCS San Raffaele
-
Contact:
- Fabrizio Stocchi, MD PhD
- Phone Number: +390652252311
- Email: fabrizio.stocchi@sanraffaele.it
-
Contact:
- Laura Vacca, MD PhD
- Phone Number: +390652252311
- Email: laura.vacca@sanraffaele.it
-
Rome, Italy, 00163
- Recruiting
- IRCCS San Raffaele Roma
-
Contact:
- laura vacca
- Phone Number: +390652252311
- Email: laura.vacca@sanraffaele.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
• Male and female of every ethnic group, age 30 to 80 years
- Diagnosis of Parkinson's disease according UK Brain Bank Criteria
- Hoehn &Yahr: stage 1 to 3
- Patients with diagnosis of sustained depression
- Hamilton Depression Rating Scale score (HAM-D-17) ≥ 14
- Beck Depression Inventory score (BDI)≥13
- Stable doses of antiparkinsonian drugs for at least 4 weeks.
- Patients able to understand and provide written informed consent
- Female patients in post-menopausal state with at least one year absence of vaginal bleeding or spotting or be surgically sterile
- Women of childbearing potential must use an acceptable method of contraception
- Men with a potentially fertile partner must have had a vasectomy or be willing to use an acceptable method of contraception for the duration of the study
Exclusion Criteria:
• Atypical Parkinsonism.
- Subjects at risk of suicide (with a score ≥ 3 at the Item 3 of the HAM-D-17)
- Any significant psychiatric, metabolic and systemic significant concomitant disease
- Patients with clinically significant out of range laboratory values
- Patients with history of epileptic seizures
- Subjects with Dopa Dysregulation Syndrome (DDS)
- Subjects treated with irreversible IMAO and IMAO-A
- Use of vortioxetine in the past 30 days
- Patient treated with oral anticoagulant
- Patients participating in a clinical trial in the last 6 weeks
- Patients with moderate-severe cognitive decline not able to provide consent form
- Patients currently lactating or pregnant or planning to become pregnant during the duration of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vortioxetine
first visit medical and pharmacological history will be collected and ECG, laboratory tests and clinical assessment will be performed.
After verifying the absence of significant abnormalities at the ECG and laboratory tests and after confirming all inclusion and exclusion criteria, subjects will perform the second visit (Week 1 - Visit 2) to receive study drug (Brintellix drops 20 mg/ml).
All subjects will be instructed to take Vortioxetine 1 drop every day after lunch, increasing of 1 drop per day arriving to 10 drops per day.
After 5 days from the beginning of treatment, subject will be contacted by phone to check on tolerability and in absence of side effects, the dosage will be increased to 10 drops per day (Visit 3- Phone contact).
At Week 4-8-12 (Visits 4-5-6) patients will return to the site to perform all clinical evaluations required and to receive study drug.
Visit 7 subjects will return to the site to perform all the assessment required by protocol.
|
16 weeks for each participant.
During the first visit a collection of medical and pharmacological history will be collected and ECG, laboratory tests and clinical assessment will be performed.
After verifying the absence of significant abnormalities at the ECG and laboratory tests and after confirming all inclusion and exclusion criteria, subjects will perform the second visit to receive study drug (Brintellix drops 20 mg/ml).
All subjects will be instructed to take Vortioxetine 1 drop every day after lunch, increasing of 1 drop per day arriving to 10 drops per day.
After 5 days from the beginning of treatment, subject will be contacted by phone to check on tolerability and in absence of side effects, the dosage will be increased to 10 drops per day.
At Week 4-8-12 patients will return to the site to perform all clinical evaluations required and to receive study drug.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: through study completion, an average of 1 year
|
The primary endpoint of this study will be to verify tolerability and safety of vortioxetine in the treatment of sustained depression in PD.
The non worsening of motor disability evaluated through Unified Parkinson's Disease Rating Scale (UPDRS) will be the tolerability end point.
|
through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Vortioxetine in the decrease of depression
Time Frame: through study completion, an average of 1 year
|
The secondary endpoint will be to demonstrate the efficacy on depression: efficacy measure will include Hamilton Depression Rating Scale
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Depression
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Tranquilizing Agents
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Serotonin Antagonists
- Anti-Anxiety Agents
- Serotonin 5-HT3 Receptor Antagonists
- Selective Serotonin Reuptake Inhibitors
- Vortioxetine
Other Study ID Numbers
- VorDe-PD
- 2018-004112-21 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on Vortioxetine
-
H. Lundbeck A/SCompleted
-
H. Lundbeck A/SCompletedPharmacokineticsChina
-
H. Lundbeck A/SCompleted
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedSingle Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating TabletsMajor Depressive Disorder (MDD)India
-
H. Lundbeck A/STakedaCompletedDepressive Disorder, MajorFinland, Estonia
-
H. Lundbeck A/SCompletedAttention Deficit Hyperactivity DisorderUnited States
-
H. Lundbeck A/SCompletedMajor Depressive DisorderBulgaria, Estonia, Latvia
-
H. Lundbeck A/SCompleted
-
Rush University Medical CenterElMindA Ltd; Takeda Pharmaceuticals North America, Inc.CompletedMajor Depressive DisorderUnited States